Bifogade filer
PDF
Kurs
+1,98%
Likviditet
0,10 MSEK
Kalender
| Tid* | ||
| 2025-03-13 | 13:30 | Kvartalsrapport 2025-Q3 |
| 2025-01-08 | N/A | Extra Bolagsstämma 2025 |
| 2024-11-28 | - | Kvartalsrapport 2025-Q2 |
| 2024-10-12 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2024-09-16 | - | Kvartalsrapport 2025-Q1 |
| 2024-06-26 | - | Bokslutskommuniké 2024 |
| 2024-03-27 | - | Kvartalsrapport 2024-Q3 |
| 2023-12-21 | - | Kvartalsrapport 2024-Q2 |
| 2023-11-15 | - | Extra Bolagsstämma 2024 |
| 2023-10-27 | - | Årsstämma |
| 2023-10-13 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2023-09-20 | - | Kvartalsrapport 2024-Q1 |
| 2023-06-23 | - | Bokslutskommuniké 2023 |
| 2023-05-09 | - | Extra Bolagsstämma 2023 |
| 2023-03-28 | - | Kvartalsrapport 2023-Q3 |
| 2022-12-21 | - | Kvartalsrapport 2023-Q2 |
| 2022-10-31 | - | Årsstämma |
| 2022-10-14 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2022-09-29 | - | Kvartalsrapport 2023-Q1 |
| 2022-06-29 | - | Bokslutskommuniké 2022 |
| 2022-03-21 | - | Kvartalsrapport 2022-Q3 |
| 2022-03-15 | - | Extra Bolagsstämma 2022 |
| 2021-12-29 | - | Kvartalsrapport 2022-Q2 |
| 2021-10-20 | - | Extra Bolagsstämma 2021 |
| 2021-10-11 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2021-09-29 | - | Kvartalsrapport 2022-Q1 |
| 2021-06-24 | - | Bokslutskommuniké 2021 |
| 2021-03-16 | - | Kvartalsrapport 2021-Q3 |
| 2020-12-14 | - | Kvartalsrapport 2021-Q2 |
| 2020-10-20 | - | Årsstämma |
| 2020-10-15 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2020-09-28 | - | Kvartalsrapport 2021-Q1 |
| 2020-06-25 | - | Bokslutskommuniké 2020 |
| 2020-03-12 | - | Kvartalsrapport 2020-Q3 |
| 2019-12-17 | - | Kvartalsrapport 2020-Q2 |
| 2019-10-16 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2019-10-15 | - | Årsstämma |
| 2018-09-27 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2018-09-26 | - | Årsstämma |
| 2018-06-18 | - | Extra Bolagsstämma 2019 |
| 2018-06-12 | - | Bokslutskommuniké 2018 |
| 2018-03-12 | - | Kvartalsrapport 2018-Q3 |
| 2017-09-26 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2017-09-25 | - | Årsstämma |
| 2017-09-11 | - | Kvartalsrapport 2018-Q1 |
| 2017-06-19 | - | Bokslutskommuniké 2017 |
| 2017-03-13 | - | Kvartalsrapport 2017-Q3 |
| 2017-01-01 | - | Extra Bolagsstämma 2018 |
| 2016-11-30 | - | Kvartalsrapport 2017-Q2 |
| 2016-09-06 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2016-09-05 | - | Årsstämma |
| 2016-09-05 | - | Kvartalsrapport 2017-Q1 |
| 2016-06-13 | - | Bokslutskommuniké 2016 |
| 2016-02-22 | - | Kvartalsrapport 2016-Q3 |
| 2016-02-16 | - | Extra Bolagsstämma 2017 |
| 2015-11-30 | - | Kvartalsrapport 2016-Q2 |
| 2015-09-08 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2015-09-07 | - | Årsstämma |
| 2015-09-07 | - | Kvartalsrapport 2016-Q1 |
| 2015-06-16 | - | Bokslutskommuniké 2015 |
| 2015-03-16 | - | Kvartalsrapport 2015-Q3 |
| 2014-12-01 | - | Kvartalsrapport 2015-Q2 |
| 2014-10-07 | - | X-dag ordinarie utdelning PHI 0.00 SEK |
| 2014-10-06 | - | Årsstämma |
| 2014-10-06 | - | Kvartalsrapport 2015-Q1 |
| 2014-06-30 | - | Bokslutskommuniké 2014 |
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Spotlight |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
The 1st of October 2024 is the last day of trading in warrants of series TO 4, which were issued in connection with Phase Holographic Imaging PHI AB's ("PHI" or the "Company") preferential rights issue of units that was carried out in 2022. The exercise period runs until 3 October 2024.
In connection with the Company's preferential rights issue of units carried out in the Spring of 2022, 1,346,162 warrants of series TO 4 were issued. Holders of TO 4 have the right to subscribe for one (1) new share in PHI at a price of SEK 4.63 per share during the exercise period, which runs until 3 October 2024.
In order for warrants not to expire without value, the holder is required to subscribe for new shares, by exercising warrants, no later than 17:00 on 3 October 2024, or sell warrants no later than on 1 October 2024.
An information brochure about the Company and the offer is available on the respective websites of PHI (www.phiab.com), Sedermera Corporate Finance AB (www.sedermera.se) and Nordic Issuing AB (www.nordic-issuing.se). Complete terms and instructions for warrants of series TO 4 are available on the Company's website.
Advisors
In connection with the warrant exercise, PHI has engaged Sedermera Corporate Finance AB as financial advisor, Markets & Corporate Law Nordic AB as legal advisor and Nordic Issuing AB as issuing agent.
For more information about the warrants, please contact:
Sedermera Corporate Finance AB
Tel: +46 (0)40 615 14 10
E-mail: cf@sedermera.se
Web: www.sedermera.se
Lisa Bodily
E-mail: ir@phiab.com (ir@phiab.se)
Web: www.phiab.com - Live cell imaging & analysis